Pylopass - L. reuteri DSM 17648

Pylopass™ contains one Limosilactobacillus reuteri DSM17648, a single bacterial strain identified by screening more than 700 Lactobacillus strains for one specific characteristic: the ability to bind to Helicobacter pylori cells and reduce the bacterial load.

• Mechanism: Forms clumps around H.pylori cells, which coaggregate (attach) around the bacteria and slowly remove them from the stomach and into the stool, ready to be passed out.
• Postbiotic: Can be used alongside antibiotics. The strain is inactivated using a specialist spray-drying process and works autonomously in the stomach.
• Highly selective: In our trials, DSM17648 bound several different H. pylori strains, giving it versatility across the world.
• Stomach pH: Pylopass was unaffected by high or low stomach acid between pH 2 and 8. This makes it perfect for low-acid and high-acid environments. This allows it to be used alongside PPIs.
• No refrigeration needed: The cells are inactive, so it doesn't require refrigeration, meaning it's stable at room temperature and in warmer environments that don't affect its stability.
• 200mg per serving: One capsule delivers 20 billion cells, the daily amount used in all our clinical trials.

Pylopass reduces the bacterial load of H. pylori.

Pylopass contains Lactobacillus reuteri DSM 17648 and works mechanically in the stomach; it sticks to H. pylori cells, crowds around them, and then leaves the stomach together with the bacteria.

How Pylopass works in 4 steps:

1. Travel: Pylopass makes it way into the stomach, where H. pylori lives in the stomach's mucus layer. Pylopass travels into the stomach, locating the bacteria.
   
2. Binding (Coaggregating): It makes contact with the stomach bacteria, sticking to its surface and forming large clumps around the bacteria.
   
3. Pulls: The clumps of Pylopass begin pulling the bacteria through the digestive tract and into the stool.
   
4. Clear: Pylopass with the H. Pylori leaves the stomach through the stool. Reducing the bacterial load of Helicobacter.

Pylopass™ (L. reuteri DSM 17648) 200mg capsule – 20 billion CFU (inactivated Strain)

Carrier: Maize dextrin, rice hull

Allergen-free capsule: Hydroxypropyl-methylcellulose

Hypoallergenic Formula: Free from the 14 major allergens listed in the EU Food Information for Consumers Regulation.

Important
Food supplements are not a substitute for a varied and balanced diet and a healthy lifestyle. Do not exceed the recommended intake. This page is general information about an ingredient and the research published on it. It is not medical advice, and nothing here should be taken as a claim that this product treats, prevents or cures any disease. If you have persistent digestive symptoms, or think you may have an infection, see your doctor.

1. Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H, Lang C. Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: a pilot study. Probiotics Antimicrob Proteins. 2015;7(2):91–100. PubMed 25481036 · DOI · Free full text
   Single-blind, placebo-controlled pilot.
   
2. Mehling H, Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013;5(8):3062–3073. PubMed 23917169 · DOI · Free full text
   Single-blind, placebo-controlled crossover.
   
3. Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutrition. 2018;4:48. PubMed · DOI / free full text
   Single-blind, placebo trial.
   
4. Bordin DS, Voynovan IN, Khomeriki SG, Yanova OB, Kim VA, Bystrovskaya EV, et al. Efficacy and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori and not having absolute indications for eradication therapy.
   
5. Pop Muresan IA, Pop LL, Dumitrascu DL. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Med Pharm Rep. 2019;92(4):352–355. PubMed 31750434 · DOI · Free full text
   Randomised controlled.
   
6. Mihai C, Mihai BM, Dranga M, Cardoneanu A, Cijevschi Prelipcean C. Lactobacillus reuteri — an alternative in the first-line of Helicobacter pylori eradication. Farmacia. 2019;67(5):871–876. PubMed · DOI / free full text
   Randomised trial.
   
7. Parth K, Prudhivi R, Palatherya S, Abbas SK, Varsha K, Niharika BV, et al. Efficacy of Lactobacillus reuteri supplementation in eradication of H. pylori: a comparison study with triple drug therapy. Journal of Pharmaceutical Research International. 2021;33(52B):151–159. Novonesis white paper.
   Randomised, double-blind, controlled.
   
8. Yang CH, Liang LP, Lv PJ, Liu L, Wang SQ, Wang ZQ, et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. PubMed · DOI
   Randomised, double-blind, placebo-controlled.
   
9. Parolova NI, Kornienko EA, Antonov PV, Egorova MB, Gorbunov EF, Dmitrienko MA. An innovative approach in the treatment of H. pylori infection in children. Russian Medical Journal (RMJ). 2015;22:1339–1340. Novonesis white paper.
   
10. Kornienko EA, Parolova NI, Ivanov SV, Polev DS, Zykin PA, Kondratenko YD, et al. Gastric microbiota and probiotics opportunities in Helicobacter pylori eradication in children. Gastroenterology & Hepatology: Open Access. 2020;11(1):13–23. DOI / free full text
    Randomised, double-blind, placebo-controlled.
    
11. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105–110. PubMed · DOI
    
12. Lang C, Böttner M, Holz C, Veen M, Ryser M, Reindl A, Pompejus M, Tanzer JM. Specific Lactobacillus/mutans Streptococcus co-aggregation. J Dent Res. 2010;89(2):175–179. PubMed · DOI

Take one capsule daily with or without food. The capsule can be opened and mixed with food if needed.

We suggest taking it daily for at least three months to feel the best effects. Pylopass can be used alongside antibiotics, proton pump inhibitors, acid blockers and antacids.

We recommend taking Pylopass with the Toxaprevent Sachets. Toxaprevent is designed to bind to histamine and ammonium, both produced by the bacteria.